DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/wpxgdn/infantile) has announced the addition of the "Global Infantile Hemangiomas Pipeline Review - H2 2013" report to their offering.
'Infantile Hemangiomas - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Infantile Hemangiomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Infantile Hemangiomas.
The analysis is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
- A snapshot of the global therapeutic scenario for Infantile Hemangiomas.
- A review of the Infantile Hemangiomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Infantile Hemangiomas pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
-
Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Infantile Hemangiomas.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
-
Devise corrective measures for pipeline projects by understanding
Infantile Hemangiomas pipeline depth and focus of Indication
therapeutics.
Key Topics Covered:
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Infantile Hemangiomas Overview
Therapeutics Development
An Overview of Pipeline Products for Infantile Hemangiomas
Companies Involved in Infantile Hemangiomas Therapeutics Development
Drug Profiles
- nadolol
- propranolol hydrochloride
- propranolol hydrochloride
- timolol maleate
- timolol maleate
- timolol maleate
-
propranolol hydrochloride
Appendix
Companies Mentioned
- InfectoPharm Arzneimittel und Consilium GmbH
- Laboratoires Pierre Fabre SA
For more information visit http://www.researchandmarkets.com/research/wpxgdn/infantile
